NCT00118183 2013-06-04
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
National Cancer Institute (NCI)
National Cancer Institute (NCI)